VBI Vaccines (NASDAQ:VBIV) Receives New Coverage from Analysts at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of VBI Vaccines (NASDAQ:VBIV – Get Free Report) in a report released on Sunday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

VBI Vaccines Stock Down 2.1 %

NASDAQ:VBIV opened at $0.73 on Friday. VBI Vaccines has a one year low of $0.45 and a one year high of $1.54. The stock has a 50 day moving average price of $0.62 and a 200 day moving average price of $0.62.

VBI Vaccines (NASDAQ:VBIV – Get Free Report) last posted its quarterly earnings results on Wednesday, May 15th. The biopharmaceutical company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.02). VBI Vaccines had a negative net margin of 881.79% and a negative return on equity of 525.42%. The company had revenue of $1.21 million during the quarter, compared to analyst estimates of $2.85 million. As a group, equities analysts forecast that VBI Vaccines will post -1.23 earnings per share for the current fiscal year.

About VBI Vaccines

(Get Free Report)

VBI Vaccines Inc, a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.

Receive News & Ratings for VBI Vaccines Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for VBI Vaccines and related companies with MarketBeat.com’s FREE daily email newsletter.